The Securities Market Division of the Korea Exchange has decided to continue its review of Dongsung Pharmaceutical's improvement plan implementation.
The company requested the review on May 22, 2026 after receiving an improvement period last August, but the committee determined further evaluation is needed.
As a result, trading of Dongsung Pharmaceutical shares remains suspended, increasing the likelihood of delisting and exposing investors to significant loss risk.
[AI Summary]Dongsung Pharmaceutical's trading suspension is prolonged as the corporate review committee continues its deliberation on the company's improvement plan implementation. This signals potential loss of listing eligibility, severely impacting shareholder value. Investors must be cautious of high uncertainty and delisting risk.
KOSPI Filing Information
Other Market Notice (Corporate Review Committee Continuation Decision Notice)